Positron Finalizes Acquisition of Manhattan Isotope Technology, LLC

FISHERS, Ind., Jan. 17, 2012 /PRNewswire/ — Positron Corporation (OTCBB: POSC),
a leading molecular imaging company specializing in the field of nuclear
cardiology is pleased to announce the acquisition of Manhattan Isotope
Technology, LLC (MIT). Positron has acquired all of the assets, business
operations and retained all employees of MIT. In exchange, MIT shall receive
cash advances, assumption of certain indebtedness and earn-out consideration of
$3,500,000 based on 20 percent of the net income from sales relating to
radioisotope and radiopharmaceutical operations of MIT.

Positron, through its wholly owned subsidiary MIT, is the only commercial
resource in the United States with practical knowledge and experience in all
stages of strontium-82 (Sr-82) production, and spent generator lifecycle
management. Positron will focus on increasing Sr-82 supply through the
processing of proton irradiated target material from domestic & foreign
suppliers and recycling Sr-82 from spent generators. MIT seeks to become the
first supplier to provide Active Pharmaceutical Ingredient (API) grade Sr-82 in
the U.S. besides the United States Department of Energy. In an effort to expand
Positron’s radioisotope product offerings, MIT possesses the unique and
specialized expertise in the production of additional radioisotopes, such as
germanium-68, selenium-72 and others, which are currently only supplied by the
U.S. Government.

In pursuit of securing a proprietary supply of radioisotopes for cardiac PET
imaging, Positron plans to build and operate the world’s largest commercial high
energy/high current cyclotron (70MeV) in the U.S. With the addition of MIT,
Positron gains the ability to develop internal processing capabilities, gain
regulatory approvals and establish a broad multiple product customer base
further enhancing the timeliness of launch and long term value of this project.
Positron’s planned cyclotron facility, once completed, will become the workhorse
of high energy radioisotope production in North America, providing a reliable,
secure, indigenous supply of radioisotopes therefore stabilizing and building
confidence throughout the cardiac PET market and nuclear medicine community
overall. Positron is committed to advancing the practice and technology of
Nuclear Cardiology and with our integrated solution will play the largest role
in the future and longevity of the industry.

Commenting upon the significance of the new company, MIT President Jason Kitten
stated, “The staff at MIT brings decades of combined experience in isotope
manufacturing and high consequence radiological facility engineering and design.
With Positron’s vertically integrated approach and foresight in developing a
robust solution to the isotope supply limitations, Positron is well positioned
to become a total solutions provider expanding the U.S. market while taking its
total solution strategy global.”

About Positron: Positron Corporation is a leading molecular imaging company
providing innovative nuclear medicine technologies and services that are
reshaping the field of nuclear cardiology. Through proprietary PET imaging
systems and radiopharmaceutical solutions, Positron enables healthcare providers
to more accurately diagnose disease and improve patient outcomes while
practicing cost effective medicine. Positron has gained significant traction in
a diverse industry and continues their strong commitment to excellence and
advancing cardiac imaging solutions. More information about Positron is
available at www.positron.com.

Forward Looking Statements: Statements in this document contain certain
forward-looking statements within the meaning of Section 27A of the Securities
Act of 1933 and Section 21E of the Securities Exchange Act of 1934, as amended.
These statements are based on many assumptions and estimates and are not
guarantees of future performance. These statements may involve known and unknown
risks, uncertainties and other factors which may cause the actual results,
performance or achievements of Positron Corporation to be materially different
from future results, performance or achievements expressed or implied by such
forward-looking statements. Positron assumes no obligation to publicly update or
revise these forward-looking statements for any reason, or to update the reasons
actual results could differ materially from those anticipated in these
forward-looking statements, even if new information becomes available in the
future. Our actual results may differ materially from the results anticipated in
these forward-looking statements due to a variety of factors, including, without
limitation those set forth as “Risk Factors” in our filings with the Securities
and Exchange Commission.

SOURCE Positron Corporation